Answers are grounded in this paper and cite their sources.
This protocol outlines the use of N-glycocapture analysis to identify differentially expressed glycoproteins in rectal cancer. We compare glycoprotein profiles from four tissue types: healthy adjacent tissue, tumor tissue pre-treatment, tumor tissue post-treatment, and recurrent tumor tissue, all derived from patients with Stage III CRC harboring the KRAS mutation. The aim is to uncover biomarkers associated with treatment response and recurrence, potentially leading to personalized treatment strategies for rectal cancer. Expected results include the identification of specific glycoproteins and pathways dysregulated in CRC, which could serve as biomarkers for predicting treatment outcomes and guiding therapeutic decisions. This protocol is expected to contribute to the advancement of personalized medicine in rectal cancer management.
No takes yet. Share an insight, caveat, or question.
Zubair et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: